Close Menu

NEW YORK(GenomeWeb) – HealthTell said today that it has received a $225,000 SBIR grant from the National Institutes of Health.

The funds will support work to evaluate the effectiveness of the company's immunosignature technology in the diagnosis of brain cancer, and glioblastoma multiforme, specifically.

According to HealthTell, the company aims through the project to demonstrate its platform's ability to distinguish primary brain cancers from brain cancers arising as metastases from other sites; and to differentiate brain cancer subtypes and grades of malignant gliomas.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.